The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Magnus Ofstad. In this article, we will summarize the ...

Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

There are currently six states with active Prescription Drug Affordability Boards (PDABs) — Colorado, Maryland, Washington, Oregon, New Hampshire, ...